Artificial intelligence is increasingly moving from medical imaging and clinical decision support into the continuous monitoring systems used during procedures. Masimo, a Danaher company, has received CE Mark approval for smartSedLine, a next-generation brain function monitor that uses an AI-powered Patient State Index (PSi) algorithm to make anesthesia monitoring more responsive to changes in brain activity.
Anesthesia monitoring is a real-time problem. A patient’s brain activity can change rapidly during induction and throughout a procedure, leaving clinicians dependent on physiological signals that need to be interpreted quickly and reliably.
Masimo is attempting to improve one part of that equation with smartSedLine, an updated version of its SedLine brain function monitoring technology. The company announced that the system’s AI-powered Patient State Index has received CE Mark, clearing it for availability in applicable European markets. The technology remains 510(k) pending in the United States.
The new system is designed to process four real-time, bilateral frontal electroencephalogram (EEG) waveforms and translate that data into several parameters that clinicians can use to assess brain function and anesthesia state.
Its principal output is PSi, a numerical index from 0 to 100 intended to reflect a patient’s level of sedation.
The important change is not simply the addition of AI to an existing monitor. Masimo says the new algorithm is designed to address two specific weaknesses in the previous-generation SedLine system: responsiveness during anesthesia induction and stability when EEG power is low.
That second issue can be particularly relevant for older and critically ill patients, whose EEG signals may be weaker.
In practical terms, smartSedLine is designed to make PSi respond more quickly when brain activity changes while reducing instability in situations where the underlying EEG signal is less pronounced.
That is a narrower and more clinically focused application of AI than the generative systems dominating the technology sector.
There is no chatbot involved and no autonomous clinical decision-making claim. Instead, an algorithm continuously analyzes a stream of physiological data and produces a numerical representation that clinicians can incorporate into their assessment.
That distinction matters as artificial intelligence enters regulated healthcare environments.
Medical AI systems must demonstrate more than technical performance. Developers need to establish that algorithms behave consistently, perform appropriately across patient populations and fit into clinical workflows without introducing new risks.
Masimo’s announcement therefore sits at the intersection of AI, medical devices, EEG monitoring and clinical decision support.
The company says smartSedLine continuously processes four bilateral frontal EEG waveforms, giving clinicians direct visibility into the underlying signal rather than relying exclusively on the derived PSi value.
That architecture provides an important layer of transparency. A clinician can view the EEG information alongside the algorithm-generated index, rather than treating the AI output as an isolated recommendation.
Masimo is positioning the technology as part of its broader Brain Health Platform, which also includes O3 Regional Oximetry. The strategy reflects a larger movement in medical-device development toward combining multiple physiological measurements with increasingly sophisticated algorithms.
The broader healthcare technology market is already moving in that direction. AI is being deployed across medical imaging, patient monitoring, diagnostics and clinical documentation, while companies such as GE HealthCare, Philips, Medtronic and Siemens Healthineers are incorporating algorithmic intelligence into increasingly connected clinical systems.
The challenge is translating AI capabilities into measurable improvements in care rather than simply adding algorithms to existing devices.
For anesthesia teams, responsiveness and signal stability have practical consequences. An index that reacts too slowly could lag behind physiological changes. An unstable index under weak EEG conditions could create additional uncertainty precisely when clinicians are treating vulnerable patients.
Masimo’s stated goal is therefore relatively specific: improve the reliability of the signal clinicians use to understand a patient’s response to anesthesia.
The company’s chief medical officer, Basil Matta, described the technology as an application of advanced AI techniques to brain-function monitoring. He said the objective is a more responsive PSi that better reflects underlying brain activity.
It is worth separating that claim from broader conclusions about clinical outcomes.
CE Mark authorization establishes regulatory conformity for the applicable market, but it does not by itself demonstrate that the technology improves postoperative outcomes, reduces complications or produces superior clinical decisions in every setting. Those questions require clinical evidence and real-world evaluation.
The technology’s potential value will ultimately depend on how anesthesiologists use the additional information.
The PSi index is intended to provide a simplified representation of sedation state, while the underlying EEG waveforms can offer additional context. That combination could be useful in situations where physiological responses vary substantially between patients.
Personalization is becoming a recurring theme in healthcare AI. Rather than applying a single static threshold to every patient, algorithms can potentially help clinicians interpret complex signals in ways that account for changing physiological conditions.
But personalization also raises questions around validation, explainability and clinician trust.
For enterprise healthcare organizations considering AI-enabled medical devices, the adoption criteria therefore extend beyond algorithm performance. Hospitals will need to consider regulatory status, interoperability, clinician training, cybersecurity, maintenance and the quality of evidence supporting the technology.
The U.S. regulatory pathway remains particularly relevant for Masimo. smartSedLine PSi is currently 510(k) pending in the United States, meaning U.S. availability depends on FDA clearance.
Masimo’s move illustrates where clinical AI may be headed next: not necessarily toward autonomous medicine, but toward continuous interpretation of high-volume physiological data.
EEG produces a stream of information that is difficult to reduce to a single number without losing context. AI can potentially help convert that stream into more useful indicators while leaving the clinical decision with the care team.
If smartSedLine performs as intended, its significance will be less about replacing anesthesiologists and more about improving the quality and timing of information available to them.
That is a more modest vision of medical AI—but potentially a more practical one.
Market Landscape
The medical AI market is expanding from image analysis into continuous patient monitoring, clinical decision support and physiological signal processing. These applications require a different development model from consumer AI because algorithms must operate reliably on real-time clinical data and fit within regulated medical-device workflows.
Masimo’s approach combines continuous EEG acquisition with an AI-derived index. Its principal competitive context includes established anesthesia and patient-monitoring platforms from GE HealthCare, Philips and Dräger, as well as specialized neurological monitoring technologies.
The differentiation is increasingly shifting toward software. Sensors can generate enormous amounts of physiological data, but clinicians need systems that convert those signals into interpretable information without obscuring the underlying evidence.
AI-powered monitoring could become particularly relevant as hospitals face growing demand for more individualized care and more efficient use of clinical staff.
The regulatory environment remains central. The FDA has authorized a rapidly growing number of AI-enabled medical devices, but healthcare providers continue to face questions about validation, transparency, monitoring and how algorithmic performance changes across patient populations.
For Masimo, CE Mark approval represents an important commercialization step, while the pending U.S. 510(k) application will determine the product’s path into the American market.
Top Insights
- Masimo’s smartSedLine received CE Mark, introducing an AI-powered PSi algorithm designed to provide more responsive anesthesia monitoring from continuous bilateral EEG signals.
- The technology targets two specific monitoring challenges: faster PSi response during induction and greater stability when EEG power is low in vulnerable patients.
- AI remains clinician-facing rather than autonomous, converting continuous EEG information into an index and parameters intended to support anesthesiologists’ assessment.
- Regulatory approval does not equal clinical-outcome proof, making post-market experience and independent evidence important as AI-enabled monitoring technologies enter routine care.
- The development expands medical AI beyond imaging, highlighting the growing role of algorithms that continuously interpret physiological signals during real-time clinical workflows.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
